PuraPharm Corporation Limited
HKSE: 1498.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Yu Ling Chan
- Employees
- 479
- Headquarters
- Tai Po, Hong Kong SAR China
- IPO year
- 2015
- Market cap
- HK$133.9M
- Website
- https://www.purapharm.com
Loading 1498…
Loading profile data…Frequently asked questions about 1498
What does PuraPharm Corporation Limited (1498.HK) do?
PuraPharm Corporation Limited, an investment holding company, researches, develops, produces, and sells concentrated Chinese medicine granule (CCMG) and Chinese healthcare products in Hong Kong, Mainland China, and internationally. It operates through five segments: China CCMG, Hong Kong CCMG, Chinese Healthcare Products, Clinics, and Plantation...
Where does 1498.HK trade?
PuraPharm Corporation Limited (1498.HK) trades on the Hong Kong Stock Exchange.
What sector is 1498.HK in?
PuraPharm Corporation Limited (1498.HK) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of PuraPharm Corporation Limited?
Yu Ling Chan is the chief executive officer of PuraPharm Corporation Limited (1498.HK).
Where is PuraPharm Corporation Limited headquartered?
PuraPharm Corporation Limited is headquartered in Hong Kong SAR China.
Does 1498.HK pay a dividend?
PuraPharm Corporation Limited (1498.HK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 1498.HK go public?
PuraPharm Corporation Limited (1498.HK) completed its initial public offering in 2015.